Voriconazole-Associated Periostitis: New Insights into Pathophysiology and Management.
February 6, 2022
|
JBMR Plus.
|
Bennett MJ, Balcerek MI, Lewis EA, Zhang RL, Bachmeier C, Tey S, Faux S, Girgis L, Greenfield JR, Lazarus S.
|
1. Introduction
Voriconazole is a frequently used antifungal in the post-transplant setting and has been associated with periostitis with long-term use.( 1 ) The true prevalence of voriconazole-associated periostitis (VAP) is unknown; however, retrospective studies suggest this adverse effect may occur in up to 15% of patients on voriconazole.( 1 , 2 , 3 ) Risk factors for developing VAP are poorly understood, and treatment options are limited. VAP shares common clinical features with sub